Prospective Multicenter Study Evaluating a Combined Circulating Tumor DNA and Circulating Tumor RNA Liquid Biopsy in Metastatic Non–Small Cell Lung Cancer (LIQUIK)
JCO Precision Oncology · 2025
DOI: 10.1200/po-25-00181 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift JCO Precision Oncology, 2025. Verfasst von Jens Samol und 12 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology, Tan Tock Seng Hospital, Singapore. Hauptthemen laut MEDLINE: Circulating Tumor DNA, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, RNA, Neoplasm. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE To evaluate the performance of a circulating tumor DNA (ctDNA) and circulating tumor RNA (ctRNA) liquid biopsy, LiquidHALLMARK (LHM), compared with tissue next-generation sequencing (NGS) and Guardant360 CDx (G360 ctDNA) liquid biopsy for biomarker detection in metastatic nonsquamous non–small cell lung cancer. PATIENTS AND METHODS This multicenter, prospective study (ClinicalTrials.gov identifier: NCT04703153 ) enrolled patients across the United States and Singapore. Patients were tested with tissue NGS, LHM, and G360 ctDNA. The primary objective was noninferiority of LHM ctDNA to tissue NGS and G360 ctDNA. Secondary analyses included turnaround time (TAT), overall response rate (ORR), and progression-free survival (PFS), with exploratory analysis of the clinical utility of ctRNA. RESULTS LHM ctDNA (48.2%) detected 11.4% fewer biomarker-positive patients than tissue NGS (59.6%) and did not meet noninferiority criteria. Compared with tissue NGS, LHM ctDNA and G360 ctDNA were concordant in 72.1% and 66.1% of patients, establishing noninferiority of LHM ctDNA to G360 ctDNA ( P = .002). TAT was shorter for LHM ctDNA than for tissue NGS (mean 9.7 v 21.7 days; P < .001). ORR/PFS was similar in patients receiving targeted therapy based on all three assays. Addition of ctRNA increased the diagnostic yield of tissue NGS–confirmed gene rearrangements by 28.6% relative to LHM ctDNA and all actionable biomarkers by 15.6% relative to G360 ctDNA. LHM ctDNA and ctRNA (51/68) detected 8.8% more biomarker-positive patients than G360 ctDNA (45/68), demonstrating superiority of LHM ctDNA and ctRNA ( P = .001). CONCLUSION LHM ctDNA is noninferior to G360 ctDNA, but not tissue NGS. Treatment outcomes based on liquid biopsy are comparable with those based on tissue NGS. Incorporation of ctRNA into LHM ctDNA improves the diagnostic yield of actionable, tissue NGS–confirmed gene rearrangements.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Medical Oncology, Tan Tock Seng Hospital, Singapore.
- John Hopkins University, Baltimore, MD.
- Lee Kong Chian/NTU, School of Medicine, Singapore.
- Lucence Diagnostics Pte Ltd, Singapore.
- Lucence Health Inc, Palo Alto, CA.
- University of Miami Sylvester Comprehensive Cancer Center, Miami, FL.
ORCID-Profile: Jens Samol, Jonathan Poh, Richa Dawar, James Orsini, Katherine Scilla, Chee Keong Toh, Boon Cher Goh, Gilberto Lopes
Zitieren
APA
Samol, J., Ng, D., Poh, J., Tan, M. H., Dawar, R., Carney, J., Orsini, J., Scilla, K., Tan, Y. O., Chin, T. M., Toh, C. K., Goh, B. C., & Lopes, G. (2025). Prospective Multicenter Study Evaluating a Combined Circulating Tumor DNA and Circulating Tumor RNA Liquid Biopsy in Metastatic Non–Small Cell Lung Cancer (LIQUIK). JCO Precision Oncology. https://doi.org/10.1200/po-25-00181
Vancouver
Samol J, Ng D, Poh J, Tan MH, Dawar R, Carney J, et al. Prospective Multicenter Study Evaluating a Combined Circulating Tumor DNA and Circulating Tumor RNA Liquid Biopsy in Metastatic Non–Small Cell Lung Cancer (LIQUIK). JCO Precision Oncology. 2025. doi:10.1200/po-25-00181
BibTeX
@article{Samol2025,
author = {Samol, Jens and Ng, David and Poh, Jonathan and Tan, Min-Han and Dawar, Richa and Carney, Jennifer and Orsini, James and Scilla, Katherine and Tan, Yew Oo and Chin, Tan Min and Toh, Chee Keong and Goh, Boon Cher and Lopes, Gilberto},
title = {Prospective Multicenter Study Evaluating a Combined Circulating Tumor DNA and Circulating Tumor RNA Liquid Biopsy in Metastatic Non–Small Cell Lung Cancer (LIQUIK)},
journal = {JCO Precision Oncology},
year = {2025},
doi = {10.1200/po-25-00181}
}
EUVIMED